better antibody

NEWS

PRESS RELEASES

09.02.14: Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief \n

ARTICLES

FierceBiotech: Xencor spotlighted as one of 10 Next-Gen Biologics Platforms

11.10.14 – 11.12.14

10th Annual European Antibody Congress (David E. Szymkowski, Ph.D., presenting; Geneva, Switzerland)


Xencor's CEO speaks to BioWorld about XmAb5871 for rheumatoid arthritis, XmAb7195 for asthma, its IPO and partnering in China. View the Video »

ANTIBODIES BY DESIGN

Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life.

Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including seven in human clinical trials being developed by Xencor and by pharmaceutical partners.

Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.